Products for Research Use Only
RegisterLogin

Tagarafdeg

CAT: 0804-HY-153341-01Size: 1 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-153341-01Size:1 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Tagarafdeg (CFT1946) is an orally active, CRBN-based and mutant-selective bifunctional degradation activating compound (BiDAC) degrader of BRAFV600E with a DC50 of 14 nM in A375 cells. Tagarafdeg is capable of degrading BRAF V600E (Class I), G469A (Class II), G466V (Class III) mutations, and the p61-BRAFV600E splice variant. Tagarafdeg can be used in tumor research[1][2].
CAS Number
2882165-79-7
Product Name Alternative
CFT1946
UNSPSC
12352005
Target
PROTACs; Raf
Type
Reference compound
Related Pathways
MAPK/ERK Pathway; PROTAC
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/cft1946.html
Purity
99.41
Solubility
DMSO : 100 mg/mL (ultrasonic)
Smiles
CN1C(C(C(N(CCC2=O)C(N2)=O)=N1)=C3)=CC(N(CC4)CCC4(O)CC(N5CCC6(C[C@@H](N(C=NC7=CC=C8OC(C(F)=CC=C9N[S](N(C)CC)(=O)=O)=C9C#N)C(C7=C8)=O)CO6)CC5)=O)=C3F
Molecular Formula
C45H49F2N11O9S
Molecular Weight
958.00
References & Citations
[1]Sowa M E, et al. Preclinical evaluation of CFT1946 as a selective degrader of mutant BRAF for the treatment of BRAF driven cancers[J]. Cancer Research, 2022, 82 (12_Supplement) : 2158-2158.|[2]Yanke Liang. The Discovery and Characterization of CFT1946: A Potent, Selective, and Orally Bioavailable Degrader of Mutant BRAF for the Treatment of BRAF-driven Cancers. ANNUAL MEETING, American Association for Cancer Research, 2023.
Shipping Conditions
Room Temperature
Storage Conditions
4°C (Powder, protect from light, stored under nitrogen)
Scientific Category
Reference compound1
Clinical Information
Phase 1
Isoform
B-Raf; Cereblon

Alternative Products

CatalogName
GTR19231282-01Tagarafdeg
C18503-1mgCFT1946 (Tagarafdeg)

Popular Products